Compounded Semaglutide vs Brand Name: What Providers Need to Know

Semaglutide has become one of the most prescribed medications in weight management, and medical practices offering GLP-1 programs face a critical decision: prescribe brand-name products (Ozempic, Wegovy) or compounded semaglutide from a compounding pharmacy. This decision involves regulatory, clinical, quality, and financial considerations that every prescriber should understand.

This guide provides a balanced, factual comparison to help practice owners and prescribers make informed decisions for their programs and their patients.

Understanding the Products

Brand-Name Semaglutide

Brand-name semaglutide is manufactured by Novo Nordisk and is available as:

• Ozempic: FDA-approved for type 2 diabetes management (0.25mg, 0.5mg, 1mg, 2mg doses)
• Wegovy: FDA-approved for chronic weight management (0.25mg through 2.4mg escalating doses)
• Rybelsus: Oral semaglutide tablet for type 2 diabetes

These products undergo full FDA approval processes, including Phase I through Phase III clinical trials, manufacturing quality controls under Current Good Manufacturing Practice (cGMP) regulations, and ongoing post-market surveillance. The FDA’s approved drug products database contains complete approval information.

Compounded Semaglutide

Compounded semaglutide is prepared by compounding pharmacies using bulk semaglutide base or semaglutide sodium salt. These products are:

• Not FDA-approved
• Not subject to the same clinical trial requirements
• Prepared under either Section 503A (patient-specific prescriptions) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act
• Available in custom doses, concentrations, and formulations

FDA Shortage Status: The Legal Foundation

The legality of compounded semaglutide is directly tied to the FDA’s Drug Shortage Database. Understanding this connection is essential for prescribers.

How Shortages Enable Compounding

Under normal circumstances, Section 503B outsourcing facilities cannot compound copies of commercially available drugs. However, during a declared drug shortage, an exception applies: 503B facilities may compound drugs that are on the FDA drug shortage list to help address patient access problems.

When semaglutide was listed as in shortage (beginning in 2022), this exception allowed outsourcing facilities to produce compounded semaglutide at scale without patient-specific prescriptions.

When the Shortage Ends

The FDA declared the semaglutide shortage resolved in February 2025, which triggered a 60-day wind-down period for 503B facilities compounding semaglutide copies. This was a pivotal moment for thousands of practices relying on compounded supply.

Key implications when a shortage resolves:

1. 503B facilities must stop distributing compounded semaglutide copies within the wind-down period
2. 503A pharmacies operate under different rules and may retain compounding pathways (see below)
3. Practices need transition plans for patients currently on compounded semaglutide
4. Court challenges have introduced uncertainty, with some compounding pharmacies challenging FDA enforcement

Current Status (2026)

The regulatory situation continues to evolve through court challenges and potential legislative action. Practices should monitor the FDA compounding page and consult legal counsel for the most current guidance.

503A vs 503B Compounding: Key Differences for Semaglutide

Understanding the two compounding pathways is critical because they have different legal foundations for semaglutide compounding.

503A Pharmacies (Traditional Compounding)

503A pharmacies operate under state pharmacy board oversight and compound medications pursuant to individual patient prescriptions. Key characteristics:

• Prescription required: Each compounded product must be based on a valid patient-specific prescription
• State-regulated: Licensed and inspected by state boards of pharmacy
• “Essentially a copy” restriction: Cannot compound products that are “essentially a copy” of a commercially available drug unless there is a clinical difference
• No federal registration: Not registered with or routinely inspected by FDA (though FDA retains enforcement authority)

For semaglutide specifically: 503A pharmacies have argued that their formulations with clinically meaningful differences (such as different salt forms, concentrations, or combination products) are not “essentially a copy” of Ozempic or Wegovy, and therefore the shortage exception is not their legal basis for compounding.

503B Outsourcing Facilities

503B outsourcing facilities are a newer category created by the Drug Quality and Security Act of 2013. Key characteristics:

• No patient-specific prescription required: Can compound in bulk, in advance of prescriptions
• FDA-registered: Voluntarily registered with FDA, subject to federal inspection
• cGMP-like standards: Must comply with conditions similar to cGMP
• Shortage exception: Can compound copies of commercial drugs during declared shortages

For semaglutide specifically: 503B facilities relied primarily on the shortage exception. When the shortage ended, their legal basis for compounding semaglutide copies was directly impacted.

Practical Implications for Practices

Quality and Purity Considerations

Quality is a legitimate concern that prescribers should evaluate carefully. The differences between brand and compounded products are meaningful.

Brand-Name Quality Controls

Novo Nordisk manufactures semaglutide under full cGMP regulations with:

• Validated manufacturing processes reviewed by FDA
• Batch-to-batch consistency testing
• Stability data supporting labeled shelf life
• Post-market adverse event reporting systems
• FDA inspection of manufacturing facilities

Compounded Quality Variables

Compounded semaglutide quality depends on the specific pharmacy. Factors that vary include:

Source materials: The origin and quality of bulk semaglutide or semaglutide sodium used as the starting material. Not all bulk suppliers are equivalent.

Potency verification: Whether the pharmacy performs certificate of analysis (COA) testing to verify that the final product contains the labeled amount of semaglutide.

Sterility testing: For injectable formulations, sterility testing and endotoxin testing are critical. USP Chapter 797 sets standards for sterile compounding.

Beyond-use dating: Compounded products typically have shorter beyond-use dates than commercially manufactured products because stability data is more limited.

Facility standards: PCAB accreditation and similar certifications indicate higher quality standards, though accreditation is voluntary.

What Prescribers Should Verify

Before partnering with a compounding pharmacy for semaglutide, verify:

1. Third-party potency testing: Does the pharmacy test finished products for potency, not just rely on raw material COAs?
2. Sterility testing protocols: What USP 797 compliance level does the facility maintain?
3. Source material documentation: Can the pharmacy provide documentation of their semaglutide source?
4. State inspection history: Has the pharmacy had any state board actions or recalls?
5. Adverse event reporting: Does the pharmacy have a system for tracking and reporting adverse events?

For guidance on evaluating pharmacy partners, see our guide on choosing a compounding pharmacy partner.

Pricing Comparison

Cost is one of the primary drivers of compounded semaglutide adoption. The pricing gap is substantial.

Brand-Name Pricing

• Ozempic: Approximately $900 to $1,100 per month (list price without insurance)
• Wegovy: Approximately $1,300 to $1,500 per month (list price without insurance)
• With insurance: Copays vary widely, from $25 to $500+ depending on plan and formulary status
• Manufacturer savings programs: Novo Nordisk offers savings cards that can reduce cost for commercially insured patients

Compounded Semaglutide Pricing

• Typical range: $200 to $400 per month depending on dose, formulation, and pharmacy
• Some pharmacies: As low as $150 per month for lower doses
• No insurance billing: Compounded products are almost never covered by insurance
• Cash-pay only: Patients pay out of pocket, making these programs accessible to practices without insurance contracts

Revenue Implications for Practices

For cash-pay medical weight loss programs, the pricing dynamics create distinct business models:

Compounded model: Lower patient cost increases volume and accessibility. Practice margins depend on the markup structure with the pharmacy partner. Higher patient volume typically compensates for lower per-patient revenue.

Brand-name model: Higher patient cost limits the addressable market. Practices may earn dispensing margins, prior authorization fees, or program management fees. Insurance billing adds complexity but enables broader patient access.

Hybrid model: Many practices offer both options, allowing patients to choose based on their budget, insurance status, and preferences. This approach provides maximum flexibility as regulatory conditions change.

Patient Counseling Points

Prescribers have an ethical and legal obligation to ensure patients understand what they are receiving. Here are the essential counseling points for informed consent.

What Patients Should Know

1. Regulatory status: Compounded semaglutide is not FDA-approved. It is legally compounded under specific regulatory frameworks, but it has not undergone the same approval process as Ozempic or Wegovy.

2. Active ingredient: The same active ingredient (semaglutide) is used, but the final product is prepared by a compounding pharmacy rather than the brand manufacturer.

3. Quality differences: While reputable compounding pharmacies maintain high quality standards, the manufacturing processes, testing requirements, and oversight differ from brand-name production.

4. Cost differences: The significant cost savings come with tradeoffs in regulatory oversight and standardization. Patients should understand this relationship.

5. Continuity risk: If regulatory changes affect compounded semaglutide availability, patients may need to transition to brand-name products or alternative treatments.

6. Side effect reporting: Patients should report side effects to both their prescriber and the compounding pharmacy. Unlike brand medications, there is no centralized post-market surveillance system for compounded products.

Documentation Requirements

For each patient prescribed compounded semaglutide, maintain documentation of:

• Clinical indication and rationale for treatment
• Discussion of brand vs. compounded options
• Patient’s informed consent acknowledging the compounded nature of the product
• The specific pharmacy used and formulation prescribed
• Follow-up plan and monitoring schedule

What Happens When the Shortage Ends: Practice Strategies

The resolution of the semaglutide shortage created challenges for practices that built programs around compounded supply. Here are practical strategies for adaptation.

Immediate Steps

1. Audit your current patient panel: Identify how many patients are on compounded semaglutide and their treatment stage
2. Verify your pharmacy’s pathway: Confirm whether your pharmacy partner operates under 503A or 503B and understand their legal position
3. Develop transition protocols: Create clinical pathways for patients who may need to switch products

Transition Options for Patients

Brand-name transition: For patients with insurance coverage or ability to pay brand pricing, transition to Ozempic or Wegovy. This requires new prescriptions, potential prior authorizations, and dose mapping.

Alternative GLP-1 medications: If tirzepatide (Mounjaro/Zepbound) remains available in compounded form, this may be an alternative. Check the FDA Drug Shortage Database for current tirzepatide status.

503A pathway continuation: If your pharmacy partner operates under 503A and has a defensible legal position for continued compounding, patients may continue without interruption. Verify this with legal counsel.

Program diversification: Consider expanding your program to include peptide therapy, hormone optimization, or other complementary services that reduce dependence on any single medication. Karpa Health supports GLP-1 weight loss alongside peptide, TRT, and HRT programs from a single platform.

Building a Resilient Program

The semaglutide shortage experience illustrates why practices should avoid single-product dependence:

• Multi-pharmacy relationships: Work with multiple pharmacy partners so supply disruption at one source does not shut down your program
• Multi-product offerings: Offer GLP-1, peptides, and other weight management approaches so patients have options
• Flexible technology: Use platforms that can route prescriptions to the best available source as regulations evolve
• Legal counsel: Maintain a relationship with a healthcare attorney who understands compounding law

Regulatory Resources and Monitoring

Prescribers should actively monitor the regulatory environment. Key resources include:

• FDA Drug Shortage Database: Check semaglutide and tirzepatide shortage status
• FDA Human Drug Compounding: Policy updates, guidance documents, and enforcement actions
• Federal Register: Proposed and final rules affecting compounding
• Alliance for Pharmacy Compounding: Industry updates and advocacy efforts
• State Board of Pharmacy: Your state’s specific compounding regulations and enforcement actions

Summary: Key Takeaways for Prescribers

The decision between compounded and brand-name semaglutide is not purely clinical. It involves regulatory risk assessment, business model considerations, patient access priorities, and ethical obligations around informed consent.

Practices that build adaptable programs, maintain multiple pharmacy relationships, and keep patients informed about the regulatory environment will be best positioned regardless of how the compounding regulations evolve.

How Karpa Health Supports GLP-1 Programs

Karpa Health provides the operational infrastructure for medical weight loss programs, supporting both compounded and brand-name GLP-1 prescribing pathways. The platform integrates with pharmacy partners including Empower Pharmacy to enable one-click prescribing, real-time order tracking, and automated patient follow-up.

Whether your practice prescribes compounded semaglutide, brand-name medications, or both, Karpa handles patient intake, AI-assisted clinical review, pharmacy routing, and fulfillment tracking so your team can focus on patient care.

Learn more about Karpa’s GLP-1 weight loss platform or book a demo to see how it works.

This article is for informational purposes only and does not constitute legal or medical advice. The regulatory environment for compounded medications changes frequently. Practices should consult with qualified legal counsel and verify current FDA guidance before making prescribing decisions. Last reviewed: April 2026.